Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Europe's Generics Industry Takes Action To Maintain Medicines Access In Ukraine

Executive Summary

Efforts are being made across the European off-patent community to bolster the supply chain and ensure access to medicines in Ukraine, says the generics and biosimilars industry association, Medicines for Europe. It has urged the EU to take a leading role in coordinating supplies through the new emergency response body, HERA.

You may also be interested in...

Russia Sanctions, China Lockdown To Pinch Globally With Higher Freight, API Costs

With the Shanghai lockdown extended, Russian vessels blacklisted and oil prices fluctuating, global freight rates are expected to increase further. Apart from a direct hit, pharma manufacturers will also feel the ripple effect as prices of raw materials like APIs increase. Scrip spoke to Indian industry to gauge the impact.

EU Industry Condemns Invasion Of Ukraine, Gives Details Of Pharma Firms’ Donations

R&D-based pharma firms and European parallel traders are contributing to the emergency relief effort in Ukraine and to the refugee crisis by making financial donations to humanitarian organizations or sending medicines and other medical supplies directly to Ukraine.

Turbulence Ahead For Indian Firms Caught In Russia-Ukraine Conflict

Leading Indian firms with operations in the war zone stare at uncertainties and disruptions as sanctions by the US and Western allies threaten to choke the Russian economy.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts